Selective omission of sentinel lymph node biopsy (SLNB) in patients with early breast cancer limits surgical morbidity.
Adoption of this strategy relies on multidisciplinary consensus.
Understanding how SLNB omission influences guideline-based adjuvant treatment decisions, and the proportion of patients impacted, can help guide decision-making.
